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Abstract
The receptor for advanced glycation end products (RAGE) is a single transmembrane receptor of
the immunoglobulin superfamily that is mainly expressed on immune cells, neurons, activated
endothelial and vascular smooth muscle cells, bone forming cells, and a variety of cancer cells.
RAGE is a multifunctional receptor that binds a broad repertoire of ligands and mediates responses
to cell damage and stress conditions. It activates programs responsible for acute and chronic
inflammation, and is implicated in a number of pathological diseases, including diabetic
complications, stroke, atheriosclerosis, arthritis, and neurodegenerative disorders. The availability
of Rage knockout mice has not only advanced our knowledge on signalling pathways within these
pathophysiological conditions, but also on the functional importance of the receptor in processes
of cancer. Here, we will summarize molecular mechanisms through which RAGE signalling
contributes to the establishment of a pro-tumourigenic microenvironment. Moreover, we will
review recent findings that provide genetic evidence for an important role of RAGE in bridging
inflammation and cancer.
Introduction
Numerous findings, ranging from epidemiological studies
to molecular analyses of mouse models, have highlighted
a strong contribution of chronic inflammation to tumour
development [1,2]. Irrespective of the cause of cancer-
related inflammation, either driven by genetic alterations,
tissue damage or arising from preceding infection, the
generation of an inflammatory microenvironment sup-
ports tumourigenesis by promoting cancer cell survival,
proliferation, migration, and invasion [3,4]. The genera-
tion of the pro-tumourigenic microenvironment strongly
depends on the activation of several transcription factors,
mainly nuclear factor-κB (NF-κB), signal transducer and
activator of transcription 3 (Stat3) and hypoxia-inducible
factor-1α (HIF-1α) [4]. These transcription factors regu-
late the expression of important cytokines, such as
tumour necrosis factor α (TNFα), interleukin-1 and -6 (IL-
1, IL-6) that are critically involved in the crosstalk between
cancer cells and cells of the tumour stroma [5-7]. Impor-
tantly, these soluble factors and their respective receptors
recruit and activate immune cells of lymphoid and mye-
loid origin and trigger signalling pathways resulting in the
production of a large number of pro-inflammatory medi-
ators in a positive feed forward loop [4,8] (Figure 1). Yet,
the exact molecular mechanisms by which a pro-tumour-
igenic microenvironment is established and maintained,
and subsequently promotes carcinogenesis remain largely
elusive.
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Cell Communication and Signaling 2009, 7:12 http://www.biosignaling.com/content/7/1/12RAGE (receptor for advanced glycation end products), a
member of the immunoglobulin superfamily of cell sur-
face molecules, interacts with diverse ligands, including
not only advanced glycation end products (AGEs) and β-
sheet fibrils, but also several members of the S100 protein
family (S100B, S100P, S100A4, S100A6, S100A8/9,
S100A11–13), high mobility group box-1 (HMGB1), and
prions [9,10]. Despite data showing activation of multiple
signalling pathways upon RAGE ligation (Figure 2), only
little is known about proximal signalling events directly
downstream of the receptor [11,12]. Furthermore, a broad
range of evidence suggests that there is no single mode of
RAGE activation by RAGE-binding proteins; first because
of intrinsic properties of the different cell types, second
the presence of three extracellular domains capable of lig-
and binding, and third the varied extent of ligand-induced
RAGE oligomerization raising the idea of different adap-
tor proteins being recruited. The diverse properties of
RAGE ligands, their interaction with the receptor, and tis-
sue specific activation of signalling pathways are subject
of several recent reviews [13-16].
RAGE function in inflammation-associated carcinogenesisFigure 1
RAGE function in inflammation-associated carcinogenesis. RAGE is expressed in all cell types implicated in tumour 
formation, including tumour cells, endothelial cells, myeloid cells, MDSCs, and lymphocytes. Signalling pathways downstream of 
RAGE that are activated by the accumulation of its ligands (AGE, HMGB1, S100 proteins) regulate cellular interactions during 
neoplastic transformation and malignant progression: (1) A pro-tumourigenic microenvironment is established by the secre-
tion of pro-inflammatory cytokines such as TNFα, IL-1, and IL-6, and the production of RAGE ligands. (2, 3) RAGE and RAGE 
ligands activate endothelial and myeloid cells resulting in the recruitment and accumulation of further myeloid cells, including 
MDSCs. (4) MDSCs inhibit T and natural killer cells leading to T cell tolerance and impaired anti-tumour immunity. (5) RAGE 
ligands and subsequent signalling also fuel tumour cell proliferation and survival by autocrine and paracrine feed-back loops. 
MDSC, myeloid derived suppressor cell; AGE, advanced glycation end products; HMGB1, high mobility group box-1; TNFα, 
tumour necrosis factor α, IL-1, interleukin-1; IL-6, interleukin-6.Page 2 of 7
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Deciphering RAGE signalling for clinical interventionsFigure 2
Deciphering RAGE signalling for clinical interventions. RAGE is known to interact with a broad spectrum of extracel-
lular ligands and multiple signal transduction pathways have been shown to be directly (solid line) or indirectly (dotted line) 
activated upon RAGE ligation. Several tools for interference with RAGE-mediated signalling have been described: sRAGE, 
RAGE blocking antibodies and a small molecule inhibitor [21]. However, their successful use in clinical applications demands a 
comprehensive knowledge on intracellular signalling pathways and gene regulatory networks. So far, the unstructured C-termi-
nal part of RAGE has hampered many approaches to find direct interaction partners within the cytosol (A). Other signalling 
molecules (B) besides PI3K, different MAPKs, Rho GTPases and ROS might be involved in functions of RAGE. On the level of 
transcriptional regulation, NF-κB, AP-1 and Stat3 have emerged as crucial targets of RAGE signalling, nevertheless other tran-
scription factors (C) might be involved in regulation and function of RAGE as well. Finally, unravelling the RAGE-regulated 
genetic programme (D) will provide insight to the functional output of RAGE signalling. Cdc42, cell division cycle 42; Erk1/2, 
extracellular signal-regulated kinase 1/2; IκB, inhibitor of kappa B; IKK, inhibitor of kappa B kinase; JAK, Janus kinase; JNK, c-jun 
N-terminal kinase; MAPK, mitogen-activated kinase; MKK, mitogen-activated kinase kinase; NF-κB, nuclear factor kappa B; 
PI3K, phosphoinositide 3-kinase; Rac1, Ras-related C3 botulinum toxin substrate 1; ROS, reactive oxygen species; Stat3, signal 
transducer and activator of transcription.
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key players in cellular response to stress conditions, such
as inflammation [14]. Induction of acute stress results in
a transient synthesis and release of RAGE ligands, which
induce an innate repair mechanism leading to a rapid but
resolving response. However, in an environment of
chronic stress with accumulation of ligands, RAGE triggers
the conversion of acute cellular activation into sustained
cellular response and tissue dysfunction [14,17].
Regulation and function of RAGE in inflammation
Increased expression of RAGE has been documented in a
variety of acute and chronic inflammatory diseases, such
as septicaemia, rheumatoid arthritis, osteoarthritis, arteri-
osclerosis, chronic renal disease, inflammatory bowel dis-
ease, vasculitis and late diabetic complications (see
references in [18]). In the past, numerous findings have
advanced our knowledge on the molecular mechanisms
through which RAGE could contribute to cellular proc-
esses of adaptive and innate immune responses [14,15].
First, RAGE expression has been found on most key cell
types linked integrally to an immune response, i.e. mono-
cytes/macrophages, neutrophils, dendritic cells, as well as
T and B lymphocytes [19-21] (Figure 1). Second, RAGE is
expressed on endothelial cells and acts as an adhesion
receptor for leukocytes by physical interaction with β2
integrin Mac-1. Interestingly, RAGE-Mac-1 interaction is
induced by pro-inflammatory RAGE ligands in vitro and
promotes leukocyte recruitment in mouse models of
inflammation [22,23]. Third, among the broad spectrum
of extracellular ligands that trigger RAGE signalling, many
have been functionally linked with acute and chronic
immune responses [24-26]. Fourth, engagement of RAGE
induces activation of the transcription factor NF-κB and
some of its downstream target genes that are well-known
regulators of the adaptive and innate immune system
[10]. It is worthwhile to note that RAGE also exhibits a
functional NF-κB binding site in its proximal promoter
and has been shown to be a direct target gene of NF-κB
signalling [27]. This might explain, at least in part, why
RAGE expression is absent or very low in normal adult tis-
sues, except for the lung, and increases under stress and
pathological conditions [28-30]. Furthermore, ligands of
RAGE have been shown to accumulate and trigger intrac-
ellular activation of NF-κB at sites of tissue damage and
inflammation [31]. This interconnected signalling ena-
bles a cycle of prolonged cellular response supporting the
establishment of chronic tissue alterations [10]. In addi-
tion, sustained NF-κB signalling in response to RAGE acti-
vation is also mediated by de novo RelA (p65) mRNA
synthesis, which results in a growing pool of transcrip-
tionally active NF-κB, overriding endogeneous negative
feedback mechanisms [32].
Important insights regarding the specific function of
RAGE in pathological conditions affected by innate and
adaptive immune responses have been obtained from
mouse models in which Rage signalling was inhibited.
This was achieved by (i) administration of blocking anti-
bodies or recombinant soluble RAGE (sRAGE), a trun-
cated form that acts as a potent decoy-receptor for ligands,
(ii) expression of a dominant-negative Rage (DN-Rage)
transgene in genetically modified mice, and (iii) complete
or tissue-specific deletion of Rage (Rage-/-). Treatment with
sRAGE and expression of DN-Rage interfered with inflam-
matory conditions and revealed therapeutic effects in
mouse models of diabetic atherosclerosis, delayed-type
hypersensitivity (DTH), neuroinflammatory disorder, col-
itis, periodontitis, and others [18,33]. However, it is
important to note that sRAGE affects immune responses
even in the absence of functional Rage, leading to the
assumption that its beneficial effects in mouse disease
models are not solely caused by preventing ligand engage-
ment of Rage but also of other receptors [34]. Studies with
Rage-deficient mice provided further in vivo evidence for
the central role of RAGE in initiation and perpetuation of
immune responses [18]. Although Rage-/- mice display a
mild pro-inflammatory phenotype characterized by a
moderately increased basal NF-κB activation and cytokine
expression, they are protected from lethal septic shock in
a model of cecal ligation and puncture (CLP), and survive
in a Listeria monocytogenes infection model [34,35].
While an important function of RAGE signalling is widely
accepted in myeloid cells affecting primarily the innate
immune response, opposing data were published in the
context of the adaptive immune response. On the one
hand, Liliensiek and colleagues reported that Rage-/- mice
showed unchanged onset and progression of disease in
models of DTH and experimental autoimmune encepha-
lomyelitis (EAE), suggesting a normal T cell-dependent
immune response [34]. On the other hand, specific loss of
Rage function in T lymphocytes impaired priming of
adaptive immune responses in vivo [21,36].
Regulation and function of RAGE in cancer
RAGE expression has been detected in a variety of human
tumours, including brain, breast, colon, colorectal, lung,
prostate, oral squamous cell, and ovarian cancer, as well
as lymphoma and melanoma [37]. Although our knowl-
edge on the molecular function of RAGE during neoplas-
tic transformation and malignant progression is limited,
recent experimental data ranging from in vitro analyses to
studies in mouse models and clinical data support a direct
link between RAGE activation and proliferation, survival,
migration, and invasion of tumour cells [37,38]. Moreo-
ver, gene expression studies with samples of human
patients and mouse tumour models revealed overexpres-
sion of RAGE ligands in most types of solid tumours
[24,39]. Taguchi and colleagues found that blockade of
the Hmgb1-Rage axis suppressed tumour growth in two
independent mouse models, and thereby provided for thePage 4 of 7
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during cancer development [40]. Yet, in contrast to the
concept of RAGE as a potent inducer of tumour growth
and malignant conversion, few reports raised the percep-
tion that it also has tumour-suppressive functions in dis-
tinct cell types. As an example, RAGE is highly expressed
in lung tissue, especially at the site of alveolar epithelium,
and its expression is significantly reduced in lung carcino-
mas [41,42]. This suggests that lung cancer progression
may be enhanced by loss of RAGE function and indeed re-
expression of RAGE in lung tumour cell lines reduced
their proliferation and revealed diminished tumour
growth in athymic mice [43-45]. In addition, functional
inactivation of RAGE in myoblasts resulted in reduced
myogenesis and enhanced proliferation and invasion in
vitro as well as increased tumour growth in vivo [46,47].
Nevertheless, tissue-specific differences in levels of RAGE
expression, its splice variants, and ligands give room for
the speculation that RAGE might exhibit tumour-suppres-
sive functions in tissues characterized by constitutive
RAGE expression, while it fulfils a tumour-promoting role
in tissues with inducible RAGE expression.
RAGE in inflammation-associated cancer
Given the evidence from a large body of experimental data
that signals downstream of RAGE can fuel chronic inflam-
matory conditions (see above), one could speculate on its
potential impact on creating a microenvironment that is
ideal for neoplastic transformation and malignant conver-
sion (Figure 1). Indeed, the usage of Rage-deficient mice
(Rage-/-) in well-established mouse models of inflamma-
tion-associated carcinogenesis, such as chemically
induced skin carcinogenesis and colitis-associated cancer,
provided direct genetic evidence for a novel role of Rage
signalling in linking chronic inflammation and cancer
[20,48]. Chemically induced skin carcinogenesis is one of
the best-established in vivo models to study the multistage
nature of tumour development. Moreover, it represents a
classical inflammation-associated tumour model, as its
promotion phase solely depends on repeated topical
treatments with the phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), a potent inducer of dermal
inflammation [49]. We could show that Rage-/- mice were
almost resistant to 9,10-dimethyl-1,2-benzanthracene
(DMBA)/TPA-induced skin carcinogenesis and that the
few tumours that developed in the absence of Rage were
smaller in size, less progressed, highly differentiated, and
hyperkeratotic [20]. Importantly, dramatically decreased
levels of pro-inflammatory mediators (e.g. Ptgs2, S100a8,
S100a9, and macrophage inflammatory proteins) and
reduced numbers of infiltrating immune cells accompa-
nied impaired tumour formation in Rage-/- animals. These
data suggest a severe defect in sustaining inflammatory
conditions during the promotion phase. One intriguing
finding of the study was the ability of Rage to induce its
own ligands, as we found strongly induced S100a8 and
S100a9 expression in epithelial cells only in the presence
of Rage. Hence, the S100-Rage axis might generate a feed-
forward loop that further aggravates an inflammatory
environment [20]. In addition, S100A8/S100A9 could
directly induce proliferation of tumour cells via RAGE
ligation, as was shown recently in a cell culture model
[50]. Bearing in mind the importance of the pro-inflam-
matory microenvironment in tumour development, it is
interesting to note, that bone marrow chimera experi-
ments revealed Rage expression on immune cells, but not
keratinocytes or endothelial cells, to be essential for
innate immune cell recruitment and induction of epider-
mal hyperplasia in vivo [20]. This is in line with published
data on a model of HMGB1-induced peritonitis [23]. Nev-
ertheless, Rage expression on keratinocytes might also
contribute to the transformation and malignant progres-
sion of epithelial cells, and it will be a challenge for the
future to investigate cell type-specific Rage knockout mice
using the DMBA/TPA tumour model.
In line with the data obtained from the model of inflam-
mation-associated skin carcinogenesis, Turovskaya and
colleagues demonstrated a crucial role for Rage in a mouse
model of colitis-induced cancer (CAC) [48]. Although
Rage was dispensable for initial acute inflammation, Rage-
/- mice showed defects in the transition to chronic inflam-
matory conditions and revealed significantly less
tumours. Interestingly, impaired CAC was not only
observed in Rage-/- mice, but also in wt mice after admin-
istration of mAbGB3.1, a monoclonal anti-carboxylate
glycan antibody [48]. Glycosylation of the extracellular
part of RAGE significantly increases receptor affinity for
HMGB1 and S100 proteins. In addition, carboxylated gly-
cans were found on a subset of RAGE on colon cancer cells
[51,52].
A common feature of both mouse models, chemically
induced skin carcinogenesis and CAC, was a reduced
number of Gr1+CD11b+ myeloid precursor cells in the
absence of Rage function, implying that RAGE signalling
also contributes to the development and recruitment of
myeloid-derived suppressor cells (MDSCs). Accumula-
tion of MDSCs is one of the major immunological abnor-
malities in cancer resulting in T cell tolerance and
suppression of anti-tumour immune response [53] (Fig-
ure 1). The molecular mechanisms of this phenomenon
remain largely undefined, however, a recent study demon-
strated that tumour-induced and Stat3-dependent up-reg-
ulation of S100a8 and S100a9 proteins in myeloid
precursor cells are necessary for the accumulation of
Gr1+CD11b+MDSCs [54]. Moreover, Sinha and col-
leagues found that S100a8/S100a9 produced and secreted
by tumour cells binds to Rage on MDSCs and promotes
their migration and accumulation through NF-κB signal-
ling pathways [55].Page 5 of 7
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In summary, the published data propose that RAGE sig-
nalling drives the strength and maintenance of an inflam-
matory response and serves as a key player in bridging
chronic inflammation and cancer. Accordingly, compel-
ling data from diverse animal models have provided a
rationale for targeting RAGE as a novel strategy for clinical
interventions, and thereby, hit two important compart-
ments during carcinogenesis: the transformed tumour
cells as well as the pro-tumourigenic microenvironment.
Several approaches have been considered to pharmaco-
logically antagonize RAGE or RAGE ligand-induced
pathologies, including cancer [18,35]. Despite these
promising results, the tumour-suppressive functions of
RAGE that were observed in specific tissues raise concerns
against the therapeutic use of RAGE inhibitors and ham-
per a systemic application of such. Furthermore, no long-
term studies using sRAGE, blocking antibodies, or small
molecule inhibitors are available yet, necessary to
appraise potential side effects. This is of particular interest,
as RAGE has been shown to be important for cellular
repair and tissue regeneration/homeostasis [14].
Altogether, there is an urgent need for a better and com-
prehensive understanding of the molecular mechanisms
through which RAGE executes its beneficial function dur-
ing acute responses and tissue homeostasis or contributes
to a feed-forward signalling in severe chronic disorders,
including cancer. Despite the fact that RAGE has been
identified almost two decades ago, it still retains a lot of
its mystery (Figure 2). Therefore, systemic and genome-
wide approaches will be required to solve the complexity
of RAGE-dependent signalling pathways and gene regula-
tory networks, also with respect to the functional crosstalk
with other receptors such as Toll-like receptors [56]. Even-
tually, the availability of a large variety of informative
mouse models and some distinct downstream target
genes will be a promising starting point for novel drug
development and drug assessment in the near future.
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